Current Neuro-Oncology
Volume
26 Number 21
30 September 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 21, 30 September
Chan P, Nagai Y, Wu Q, Hovsepyan A, Mkhitaryan S, Wang J,
Karapetyan G, Kamenecka T, Solt LA, Cope J, Moats RA, Hirota T,
Rich JN, Kay SA.
Advancing Clinical
Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator
Efficacy in Preclinical Models and Safety in Phase I Trials.
bioRxiv [Preprint]. 2024 Sep 21:2024.09.17.613520.
doi:
10.1101/2024.09.17.613520. PMID:
39345648. Interventional study. ˍ
Oort Q, Reijneveld JC, Sikkes SAM, Koekkoek JAF, Boele F, Young T,
Brannan C, Chalk T, Talacchi A, Mazzotta A, Narita Y, Sato H,
Miyakita Y, Shamieh O, Alrjoob W, Pace A, Petranovic D, Ploh M,
Capela A, Silva J, Hjermstad MJ, Purkart TU, Seidel C, Talhi N,
Pichler J, Höllmüller I, Brown L, Hand M, Klein M,
Aaronson NK, Uitdehaag BMJ, Taphoorn MJB, Dirven L; EORTC Quality
of Life Group and the EORTC Brain Tumor Group.
Instrumental
activities of daily living in neuro-oncology: International
validation of the EORTC IADL-BN32 questionnaire.
Eur
J Cancer. 2024 Sep 21;212:114335. doi:
10.1016/j.ejca.2024.114335. PMID:
39332215. Observational study. ˍ
Verducci C, Sloane DC, Hand R, Choe S, Jusue-Torres I, Shanker RM,
Kim M, Mallik AK, Germanwala AV, Anderson DE.
The
surgical management of third ventricle region tumors.
Clin
Neurol Neurosurg. 2024 Sep 21;246:108564. doi:
10.1016/j.clineuro.2024.108564. PMID:
39332050. Observational study˰
ˍ
Garelli G, Rovera G, Levis M, Lesca A, Pellerino A, Bruno F,
Agosti A, Mangia ML, Cioffi M, Coccarelli A, Morana G, Ricardi U,
Rudà R, Morbelli S, Zotta M.
[18F]DOPA
PET for lesion definition and contouring using different
thresholds in patients with gliomas.
Q
J Nucl Med Mol Imaging. 2024 Sep 23. doi:
10.23736/S1824-4785.24.03587-8. PMID:
39311479. Observational study˰
ˍ
Katzendobler S, Niedermeyer S, Blobner J, Trumm C, Harter PN, von
Baumgarten L, Stoecklein VM, Tonn JC, Weller M, Thon N, Weller J.
Determinants of long-term survival in
patients with IDH-mutant gliomas.
J
Neurooncol. 2024 Sep 24. doi:
10.1007/s11060-024-04826-9. PMID:
39316316. Observational study. ˍ
*Laviv Y, Regev O, Kanner AA, Fichman S, Limon D, Siegal T,
Yust-Katz S, Benouaich-Amiel A.
Stem
the blood flow: beneficial impact of bevacizumab on survival of
subventricular zone glioblastoma patients.
J
Neurooncol. 2024 Sep 24. doi:
10.1007/s11060-024-04828-7. PMID:
39316315. Observational study. ˍ
van Opijnen MP, de Vos FYF, Cuppen E, Geurts M, Maas SLN, Broekman
MLD.
The role of molecular biomarkers
in recurrent glioblastoma trials: an assessment of the current
trial landscape of genome-driven oncology.
Med
Oncol. 2024 Sep 24;41(11):250. doi:
10.1007/s12032-024-02501-7. PMID:
39316248. Observational study. ˍ
Brisson RJ, Indelicato DJ, Bradley JA, Aldana PR, Klawinski D,
Morris CG, Vega RBM.
Long-term
outcomes following proton therapy for pediatric spinal low-grade
glioma.
Pediatr
Blood Cancer. 2024 Sep 25:e31341. doi:
10.1002/pbc.31341. PMID:
39323035. Observational study˰
ˍ
Lim MS, Crimmins D.
The prognostic
utility of the neutrophil to lymphocyte ratio in paediatric brain
tumours: a retrospective case control study.
Br
J Neurosurg. 2024 Sep 26:1-7. doi:
10.1080/02688697.2024.2406804. PMID:
39324393. Observational study˰
ˍ
*Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli FR,
Biassoni V, Oriani M, Schiavello E, Ficorilli M, Nigro O, Pollo B,
Antonelli M, Donofrio V, Maggioni M, Kool M, Pecori E, Vennarini
S, Giangaspero F, Gianno F, Erbetta A, Chiapparini L, Luksch R,
Barzanò E, Meazza C, Podda M, Spreafico F, Terenziani M,
Bergamaschi L, Ferrari A, Casanova M, Chiaravalli S, Gattuso G,
Modena P, Bailey S, De Cecco L.
Long-term
outcome of the Milano-HART strategy for high-risk medulloblastoma,
including the impact of molecular subtype.
Neuro
Oncol. 2024 Sep 27:noae189. doi:
10.1093/neuonc/noae189. PMID:
39331528. Observational study. ˍ
Kebudi R, Yildirim UM, İribaş A, Tuncer S.
Optic
pathway gliomas in children: Clinical characteristics, treatment,
and outcome of 95 patients in a single center over a 31-year
period. Can we avoid radiotherapy?
Pediatr
Blood Cancer. 2024 Sep 29:e31337. doi:
10.1002/pbc.31337. PMID:
39344026. Observational study. ˍ
*Uke AD, Luharia A, Dahake S, Mishra GV, Mahakalkar C.
Exceptional Tumor Regression in
Diffuse Intrinsic Pontine Glioma Post-Radiotherapy: A Case
Study.
Am
J Case Rep. 2024 Sep 30;25:e944869. doi:
10.12659/AJCR.944869. PMID:
39348336. Case report. ˍ
Satragno C, Schiavetti I, Cella E, Picichè F, Falcitano L,
Resaz M, Truffelli M, Caneva S, Mattioli P, Esposito D, Ginulla A,
Scaffidi C, Fiaschi P, D'Andrea A, Bianconi A, Zona G, Barletta L,
Roccatagliata L, Castellan L, Morbelli S, Bauckneht M, Donegani I,
Nozza P, Arnaldi D, Vidano G, Gianelli F, Barra S, Bennicelli E,
Belgioia L; disease management team on Neuroncology of IRCCS
Ospedale Policlinico San Martino.
Systemic
inflammatory markers and volume of enhancing tissue on
post-contrast T1w MRI images in differentiating true tumor
progression from pseudoprogression in high-grade glioma.
Clin
Transl Radiat
Oncol. 2024 Aug 30;49:100849. doi:
10.1016/j.ctro.2024.100849. PMID:
39318678. Observational study. ˍ
*Sloan L, Sen R, Liu C, Doucet M, Blosser L, Katulis L, Kamson DO,
Grossman S, Holdhoff M, Redmond KJ, Quon H, Lim M, Eberhart C,
Pardoll DM, Hu C, Ganguly S, Kleinberg LR.
Radiation
immunodynamics in patients with glioblastoma receiving
chemoradiation.
Front
Immunol. 2024 Sep 13;15:1438044. doi:
10.3389/fimmu.2024.1438044. PMID:
39346903. Observational study. ˍ